ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1664

Lower Tissue Expression Of IL 6 In Patients With Giant Cell Arteritis Presenting With a Cranial Ischaemic Compication

Lorraine O'Neill1, Jennifer McCormick2, Danielle Molloy1, Douglas J. Veale1, Conor Murphy3, Geraldine M. McCarthy4, Ursula Fearon2 and Eamonn S. Molloy1, 1Rheumatology, St. Vincent's University Hospital, Dublin 4, Ireland, 2Dublin Academic Medical Centre, Translational Rheumatology Research Group, Dublin, Ireland, 3Department of Ophthalmology, Royal Victoria Eye and Ear Hospital, Dublin, Ireland, 4Medicine/Rheumatology, Mater Misericordiae University Hospital, Dublin 7, Ireland

Meeting: 2013 ACR/ARHP Annual Meeting

Keywords: giant cell arteritis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Vasculitis II

Session Type: Abstract Submissions (ACR)

Background/Purpose:

Giant Cell Arteritis (GCA) is a granulomatous systemic vasculitis with a prediliction for the aorta and it’s extracranial branches.  The majority of the morbidity associated with GCA is related to its ischaemic complications of acute visual loss and stroke.  It has previously been shown that patients with cranial ischaemic complications (CICs) due to GCA have lower temporal artery IL 6 expression and circulating levels of IL 6 than patients without CICs.1

The current study aimed to extend these previous observations by:

  1. Comparing the spontaneous release of IL 6 from cultured temporal artery explants of patients with GCA and CICs to those without CICs.
  2. Investigating the association between spontaneous release of IL 6 from the explant cultures and the presence of intimal hyperplasia and luminal occlusion on histopathology.

 Methods:           

Patients with suspected GCA underwent a temporal artery biopsy and had serum biomarkers assayed at baseline.

TAB sections were sent for review to a histopathologist who was blinded to the clinical presentation.

Additional sections were cultured for 24 hours and IL 6 expression in the  supernatants quantified  by ELISA.

Temporal artery explants from 7 patients with GCA (3 TAB positive, 4 TAB negative & 1 patient with a documented CIC) were embedded in matrigel, stimulated with recombinant IL 6 at concentrations of 20 ng/ml and 40 ng/ml and myofibroblast outgrowths observed over a 3 week period.

Results:

30 patients had a temporal artery biopsy (TAB) that was positive for GCA. 25 had a negative or inconclusive TAB but met ACR classification criteria for GCA and were therefore included in the analysis.

11/55  (20%) patients presented with an ischaemic complication attributable to GCA.

Baseline demographics were similar between those with CICs and those without. Other than their presenting CICs, there was no difference in any of the other clinical manifestations of GCA between both groups.

Cumulative steroid dose pre biopsy was higher in those presenting with a cranial ischaemic complication than those without (p =0.015) However, there was no correlation observed between cumulative steroid dose and expression of IL 6 in explant cultures.

There was a trend both towards a lower baseline CRP and IL 6 in those with CICs than those without but this was not statistically significant. (Mean CRP 33 g/L vs 49 g/L and mean IL 6 17.23 pg/ml vs 31 .83 pg/ml)

Patients with CICs had significantly lower levels of of IL 6 in explant supernatants when compared to those without CICs (Mean 8.66 ng/ml/mg biopsy weight vs 18 .92 ng/ml/mg biopsy weight, p <0.01). 

This lower tissue IL 6 production was significantly associated with both intimal hyperplasia (p < 0.03) and luminal occlusion (p < 0.01) on histopathology.

In addition, rIL 6 induced myofibroblast outgrowths at concentrations of 20 ng/ml but had a significant inhibitory effect at 40 ng/ml

Conclusion:

The study confirms the association between lower levels of IL 6 expression in patients with CICs than those without. The inhibitory effect on myofibroblast outgrowths at higher concentrations of IL 6 merits further investigation given the known involvement of myofibroblasts in the development of intimal hyperplasia and occlusion.

1. Cid et al. Circulation 2003

.


Disclosure:

L. O’Neill,
None;

J. McCormick,
None;

D. Molloy,
None;

D. J. Veale,
None;

C. Murphy,
None;

G. M. McCarthy,
None;

U. Fearon,
None;

E. S. Molloy,
None.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2013 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/lower-tissue-expression-of-il-6-in-patients-with-giant-cell-arteritis-presenting-with-a-cranial-ischaemic-compication/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology